Compare SMJF & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMJF | ACET |
|---|---|---|
| Founded | 1988 | 1947 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.7M | 77.3M |
| IPO Year | N/A | 2017 |
| Metric | SMJF | ACET |
|---|---|---|
| Price | $5.24 | $7.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $48.33 |
| AVG Volume (30 Days) | ★ 605.1K | 103.7K |
| Earning Date | 09-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $68.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $0.46 |
| 52 Week High | $5.70 | $9.47 |
| Indicator | SMJF | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 79.08 | 46.66 |
| Support Level | $4.50 | $7.36 |
| Resistance Level | $5.64 | $8.68 |
| Average True Range (ATR) | 0.39 | 0.60 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 82.21 | 30.63 |
SMJ International Holdings Inc specializes in the sale and distribution of a wide range of flooring products such as carpet tiles, broadloom carpets and vinyl tiles. The company operates under the proprietary brand 'SMJ'.The company also supplies environmentally friendly flooring products, promoting sustainable building practices in Asia. It has presence in several countries including Malaysia, Indonesia, Philippines, Hong Kong, PRC, Taiwan, Korea, Thailand, Vietnam, Brunei, and India. It generates revenue mainly through the sale and distribution of its flooring products prominently in Singapore.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).